Jinhe Biotechnology Co Stock Revenue
| 002688 Stock | 4.48 0.10 2.28% |
Jinhe Biotechnology Co fundamentals help investors to digest information that contributes to Jinhe Biotechnology's financial success or failures. It also enables traders to predict the movement of Jinhe Stock. The fundamental analysis module provides a way to measure Jinhe Biotechnology's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Jinhe Biotechnology stock.
| Last Reported | Projected for Next Year | ||
| Total Revenue | 2.2 B | 1.5 B |
Jinhe | Revenue |
Jinhe Biotechnology Co Company Revenue Analysis
Jinhe Biotechnology's Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Current Jinhe Biotechnology Revenue | 2.17 B |
Most of Jinhe Biotechnology's fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Jinhe Biotechnology Co is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Historical and Projected quarterly revenue of Jinhe
Projected quarterly revenue analysis of Jinhe Biotechnology provides investors and stakeholders with an insight into the company's performance and growth prospects. When actual revenues of Jinhe Biotechnology match or exceed analyst estimates, it positively influences investor confidence and market perception, often leading to a rise in Jinhe Biotechnology's stock price.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Jinhe Current Deferred Revenue
Current Deferred Revenue |
|
Based on the latest financial disclosure, Jinhe Biotechnology Co reported 2.17 B of revenue. This is much higher than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The revenue for all China stocks is notably lower than that of the firm.
Jinhe Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Jinhe Biotechnology's direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Jinhe Biotechnology could also be used in its relative valuation, which is a method of valuing Jinhe Biotechnology by comparing valuation metrics of similar companies.Jinhe Biotechnology is currently under evaluation in revenue category among its peers.
Jinhe Fundamentals
| Return On Equity | 0.0371 | ||||
| Return On Asset | 0.0223 | ||||
| Profit Margin | 0.04 % | ||||
| Operating Margin | 0.13 % | ||||
| Current Valuation | 5.06 B | ||||
| Shares Outstanding | 771.69 M | ||||
| Shares Owned By Insiders | 45.62 % | ||||
| Shares Owned By Institutions | 1.23 % | ||||
| Price To Book | 1.54 X | ||||
| Price To Sales | 1.55 X | ||||
| Revenue | 2.17 B | ||||
| Gross Profit | 613.79 M | ||||
| EBITDA | 387.55 M | ||||
| Net Income | 86.46 M | ||||
| Total Debt | 2.3 B | ||||
| Book Value Per Share | 2.96 X | ||||
| Cash Flow From Operations | 198.77 M | ||||
| Earnings Per Share | 0.12 X | ||||
| Number Of Employees | 2.32 K | ||||
| Beta | 0.41 | ||||
| Market Capitalization | 3.51 B | ||||
| Total Asset | 5.45 B | ||||
| Retained Earnings | 560.1 M | ||||
| Working Capital | (217.74 M) | ||||
| Annual Yield | 0.02 % | ||||
| Net Asset | 5.45 B | ||||
| Last Dividend Paid | 0.1 |
About Jinhe Biotechnology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Jinhe Biotechnology Co's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Jinhe Biotechnology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Jinhe Biotechnology Co based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Jinhe Stock
Jinhe Biotechnology financial ratios help investors to determine whether Jinhe Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Jinhe with respect to the benefits of owning Jinhe Biotechnology security.